Keywords
Pairwise Comparisons, Study-Based Registers, Clinical Trials, Randomised Controlled Trials, Network Meta-Analysis, Systematic Reviews
Pairwise Comparisons, Study-Based Registers, Clinical Trials, Randomised Controlled Trials, Network Meta-Analysis, Systematic Reviews
We added that the formula in this manuscript is an established formula in Combinatorics, and expanded the ‘Comparisons in network meta-analysis plots’ section with further details about Figure 4.
See the authors' detailed response to the review by Julie Broderick
See the authors' detailed response to the review by G. Mustafa Soomro
The pairwise comparisons reported within each randomized controlled trial are being documented in study-based registers1. This lends itself to accurate indexing and enumeration of these comparisons within the studies and then subsequent supply of immediate, highly sensitive and highly specific search results to those wishing to investigate one or more particular comparisons within systematic reviews and meta-analyses or overviews and network meta-analysis1,2.
To gain a perspective on the absolute effectiveness of a treatment it is ideal to compare all the existing medications with placebo and for relative effects with each other in pairwise comparison trials. However, some of pairwise comparisons of the medications have not been tested within trials at all. Finally, even if some of the possible pairwise comparisons have been directly tested within trials not all may be eligible for inclusion in a network meta-analysis3. This leaves a gap between the research has been done and the research that should or could have been undertaken and finding this highlights gaps in the fair testing of treatments4.
A two-arm trial will generate one pairwise comparison. A three-arm trial, however. will generate three, and a six-arm study, 15 pairwise comparisons. It is easy to lose track of how many comparisons one study can generate. This is more likely when it comes to the many direct, indirect or mixed comparisons within a network. This paper describes a simple formula for enumerating the possible number of comparisons within a single trial or planned network meta-analysis in advance.
The formula below solves this where n is the number of arms in a single study or network and N is the number of pairwise comparisons:
Where n > 0;
n is a natural number;
Then every intervention is compared to every other intervention except itself so: n*(n-1);
Because N is a bidirectional comparison (X vs. Y = Y vs. X) so: (n*(n-1))/2;
This is an established formula from combinatorics for calculating number of pairs for a number of items in a set.
The networks of 2 to 10 interventions will create networks in shapes of line, triangle, rectangle, pentagon, hexagon, heptagon, octagon, nonagon and decagon, respectively. A visual proof of a network of five interventions and (5*(5-1))/2=10 pairwise comparisons is presented in Figure 1.
Adding any new intervention to the trial or network will create n-1 new pairwise comparisons. For example, where there are 6 arms in a trial—or 6 nodes in network meta-analysis—there will be (6*(6-1))/2=15 comparisons; adding a new intervention (6+1=7) will create 7-1=6 new pairwise direct comparisons in an individual trial and 6 direct or indirect comparisons in a network meta-analysis. Although this formula has been used for other purposes such as Metcalfe’s law in telecommunication, its use in the current context is novel.
We used the open data5 from our previously published network meta-analysis6 to re-create and enumerate the comparisons within the network. Using the direct comparisons reported in the trials within the network, we applied the formula and then compared the number of potential or expected comparisons (formula-derived) and the actual or observed number reported within the network analysis.
We built a small study-based register based—thus avoiding the pitfall of multiple counting—containing all 133 included studies in our previous network meta-analysis6,7. These trials reported comparisons from 8 interventions. Using our formula, 8 interventions should create 28 unique comparisons: (8*(8-1))/2=28 (Figure 2).
We extracted the separate intervention arms from the open data to re-create the direct comparisons from within trials. The trials had either two or three arms so each study could create either two or three comparisons. As a result the 133 studies had 163 comparisons, the majority of which were duplicated. After removing these duplicates, this created 16 unique direct comparisons with between 1 and 47 studies per comparison for 8 interventions (Table 1). These 16 observed comparisons are 57% of the 28 expected by use of the formula above.
Comparison | Number of studies | Study tag |
---|---|---|
Amphetamines vs. Atomoxetine | 1 | Wigal 2005 (SLI381-404, NCT00506727) |
Amphetamines vs. Guanfacine | 1 | Taylor 2001 |
Amphetamines* vs. Methylphenidate | 6 | Coghill 2013 (SPD489-325); Efron 1997; Plizka 2000; SPD489-405 (NCT01552915); SPD489-406 (NCT01552902);Stein 2011 (NCT00393042) |
Amphetamines vs. Modafinil | 1 | Taylor 2000 |
Amphetamines vs. Placebo | 21 | Adler 2008b (NRP104.303, NCT00334880); Adler 2013 (SPD489-403, NCT01101022); Biederman 2002 (SLI 381-301); Biederman 2007 (NRP104-301, NCT00248092); Biederman 2012 (2008P000971, NCT00801229); Coghill 2013 (SPD489-325); Findling 2011 (SPD 489- 305, NCT00735371); Frick 2017 (SPD465-303, NCT00152022); Kay 2009a; Paterson 1999; Plizka 2000; Spencer 2001; SPD489-405 (NCT01552915); SPD489-406 (NCT01552902);Spencer 2006 (SLI381-314, NCT00507065); Spencer 2008 (SPD465-301, NCT00150579); Stein 2011 (NCT00393042); Taylor 2000; Taylor 2001; Weisler 2006 (SLI381-303); Winhusen 2010 (NCT00253747) |
Atomoxetine vs. Guanfacine | 1 | Hervas 2014 (SPD503-316, NCT01244490, EudraCT: 2010- 018579-12) |
Atomoxetine vs. Methylphenidate | 8 | Bedard 2015 (NCT00183391); Newcorn 2008 (B4Z-MC-LYBI); Sangal 2006 (B4Z-US-LYAV); Schulz 2012; Spencer 2002a (B4Z-MC-HFBD); Spencer 2002b (B4Z-MC-HFBK); Wang 2007 (NCT00486083, B4Z-MC-LYBR (6934)); Weisler 2012 (NCT00880217) |
Atomoxetine vs. Placebo | 41 | Adler 2008a (B4Z-MC-LYBV, NCT00190931); Adler 2009a (B4Z-US-LYDQ, NCT00190879); Adler 2009b (B4Z-US-LYCU. NCT00190736); NCT00190736); Allen 2005 (B4Z-MC-LYAS); Arnold 2006; Bain 2013 (NCT00429091); Bangs 2007 (B4Z-MC-LYAX); Bangs 2008 (B4Z-MC-LYBX, NCT00191698); Block 2009 (B4Z-US-LYCC, NCT00486122); Dell'Agnello 2009; Dittman 2011; Durell 2013 (B4Z-US-LYDZ, NCT00510276); Gau 2007 (B4Z-TW-S010, NCT00485459); Geller 2007 (B4Z-US-LYBP); Goto 2017 (B4ZJE-LYEE, NCT00962104); Harfterkamp 2012 (NCT00380692); Hervas 2014 (SPD503-316, NCT01244490, EudraCT: 2010- 018579-12); Kay 2009b; Kelsey 2004 (B4Z-US-LYBG); Lin 2016 (NCT00917371); Martenyi 2010 (B4Z-MW-LYCZ, NCT00386581); McRae-Clark 2010 (R21DA018221, NCT00360269); Michelson 2001 (B4Z-MC-LYAC); Michelson 2002 (B4Z-MC-LYAT); Michelson 2003a; Michelson 2003b; Montoya 2009 (B4Z-XM-LYDM, NCT00191945); Newcorn 2008 (B4Z-MC-LYBI); Spencer 1998; Spencer 2002a (B4Z-MC-HFBD); Spencer 2002b (B4Z-MC-HFBK); Sutherland 2012 (NCT00174226); Svanborg 2009 (B4Z-SO-LY15, EUCTR2004-003941-42-SE, NCT00191542); Takahashi 2009 (B4Z-JE-LYBC, NCT00191295); Wehmeier 2012 (B4Z-SB-LYDV, NCT00546910); Weisler 2012 (NCT00880217); Weiss 2005 (B4Z-MC-LYAW); Wietecha 2013 (NCT00607919); Wilens 2008 (B4Z-MC-LYBY, NCT00190957); Wilens 2011 (NCT00528697); Young 2011 (B4Z-US-LYCW, NCT00190775) |
Bupropion vs. Methylphenidate | 2 | Jafarinia 2012; Moharari 2012 (IRCT201012295500N1) |
Bupropion vs. Placebo | 4 | Casat 1989; Reimherr 2005; Wilens 2001; Wilens 2005 (NCT00048360) |
Clonidine vs. Methylphenidate | 4 | Connor 2000; Kurlan 2002; Palumbo 2008 (NCT00031395); van der Meere 1999 |
Clonidine vs. Placebo | 5 | Jain 2011 (NCT00556959); Kurlan 2002; Palumbo 2008 (NCT00031395); Singer 1995; van der Meere 1999 |
Guanfacine vs. Placebo | 12 | Biederman 2008 (SPD503-301, NCT00152009); Connor 2010 (SPD503-307, NCT00367835); Hervas 2014 (SPD503-316, NCT01244490, EudraCT: 2010- 018579-12); Kollins 2011 (SPD503-206, NCT00150592); McCracken 2016; NCT01069523; Newcorn 2013 (SPD503-314, NCT00997984); Rugino 2014 (NCT01156051); Sallee 2009 (SPD503-304, NCT00150618); Schahill 2001 (NCT00004376); Taylor 2001; Wilens 2015 (SPD503-312, EUCTR2011-002221-21, NCT01081132) |
Methylphenidate vs. Modafinil | 1 | Amiri 2008 |
Methylphenidate vs. Placebo | 47 | Abikoff 2009; Adler 2009c (CR011560, NCT00326391); Biederman 2006a (subsample of NCT00181571); Biehl 2016; Bron 2014; Buitelaar 1996; Casas 2013 (EudraCT: 2007-002111-82); Childress 2009 (CRIT124E2305, NCT00301236); Coghill 2013 (SPD489-325); Cook 1993; CRIT124DUS02; Dopfner 2003; Findling 2008 (NCT00444574); Ginsberg 2012 (EUCTR2006-002553-80-SE); Goodman 2016 (NCT00937040); Greenhill 2002; Greenhill 2006b (CRIT124E2301); Grizenko 2012; Herring 2012 (NCT00475735); Huss 2014 (CRIT124D2302, EUCTR2010-021533-31-DE, NCT01259492); Kooij 2004; Kurlan 2002; Lin 2014 (NCT00922636); Medori 2008 (LAMDA-I EUCTR2004- 000730-37, NCT00246220); Newcorn 2008 (B4Z-MC-LYBI); Palumbo 2008 (NCT00031395); Philipsen 2015 (EUCTR2006-000222-31-DE, ISRCTN54096201); Plizka 2000; Reimherr 2007; Rosler 2009; Schrantee 2016 (NTR3103, EUCTR2010-023654-37-NL); Simonoff 2013 (ISRCTN683849); SPD489-405 (NCT01552915); SPD489-406 (NCT01552902); Spencer 1995; Spencer 2002a (B4Z-MC-HFBD); Spencer 2002b (B4Z-MC-HFBK); Spencer 2005; Spencer 2007 (CRIT124E2302); Stein 2011 (NCT00393042); Takahashi 2014 (NCT01323192); Taylor 1987; van der Meere 1999; Weisler 2012 (NCT00880217); Wender 2011; Wigal 2004; Wigal 2015 (NCT01239030) |
Modafinil vs. Placebo | 8 | Arnold 2014 (C1538/2027/AD/US, NCT00315276); Biederman 2005 (Study 311 Cephalon); Biederman 2006b; Greenhill 2006a (Study 309 Cephalon); Kahbazi 2009; Rugino 2003; Swanson 2006; Taylor 2000 |
Among five networks reported in the final paper, the number of comparisons in these five network meta-analyses, however, varies from 6 (for 3 networks) to 11 (for 1 network) and 13 (for 1 network) (Figure 3). As visualized in Figure 3, only 21.42% to 46.42% of comparisons were eligible for pairwise meta-analysis (Table 2).
Source of comparisons | Type of comparisons | Eligibility for analyses | # of comparisons | % of comparisons | ||
---|---|---|---|---|---|---|
Direct | Indirect | Eligible | Ineligible | |||
Formula | √ | √ | √ | √ | 28=(8*(8-1))/2 | 100.00 |
Randomised trials | √ | × | √ | √ | 16 (Table 1) | 57.14 |
Pairwise meta-analysis | √ | × | √ | × | 6-13 (Figure 3)* | 21.42 to 46.42 |
Network meta-analysis | √ | √ | √ | √ | 28 (Figure 2) | 100.00 |
* There are five networks in Figure 3 and each has 6, 11, or 13 eligible comparisons. Three out of 16 comparisons from trials have not been included in any of five network plots.
From Figure 3 we can calculate that about 42% of comparisons expected through use of the formula have not been tested directly in trials. This is a direct evidence-gap. The number of missing comparisons varies between nine out of 15 in three networks with six interventions, 17 out of 28 in one network with eight interventions, and 15 out of 28 in another network with eight interventions (Figure 3). However, all 28 comparisons expected by use of the formula were utilized and reported within the network meta-analysis. It is possible that some of the comparisons predicted by the formula would have been deemed ineligible—either by adherence to a network review protocol or through post hoc exclusions—but this was not the case in this particular review (Figure 4). This diagram shows that only some of the comparisons from trials in study-based register could be included in pairwise meta-analysis. In addition, the number of comparisons in network meta-analysis (calculated by formula) is larger and inclusive of all the comparisons in the network of interventions and includes all the possible unique comparisons even if the comparisons are not in trials or in pairwise meta-analysis.
This formula can be employed when estimating the total number of comparisons (direct and indirect combined) theoretically possible within a proposed network meta-analysis. It would be possible that there would sometimes be a discrepancy between the number of comparisons theoretically possible and those actually employed within any given network meta-analysis. The formula would highlight this for researchers and readers and, before and after analyses, facilitate descriptions of why particular comparisons have not been included.
The formula produces an accurate enumeration of the potential comparisons within a single trial or network meta-analysis.
Any shortfall between the full potential of the data and the actual number of comparisons within a network meta-analysis should be possible to explain through reference to pre-stipulated eligibility criteria or post hoc exclusions.
Views | Downloads | |
---|---|---|
F1000Research | - | - |
PubMed Central
Data from PMC are received and updated monthly.
|
- | - |
Is the work clearly and accurately presented and does it cite the current literature?
Yes
Is the study design appropriate and is the work technically sound?
Yes
Are sufficient details of methods and analysis provided to allow replication by others?
Yes
If applicable, is the statistical analysis and its interpretation appropriate?
Yes
Are all the source data underlying the results available to ensure full reproducibility?
No source data required
Are the conclusions drawn adequately supported by the results?
Yes
Competing Interests: No competing interests were disclosed.
Reviewer Expertise: Systematic reviews and meta-analysis and secondary data analysis.
Is the work clearly and accurately presented and does it cite the current literature?
Yes
Is the study design appropriate and is the work technically sound?
Yes
Are sufficient details of methods and analysis provided to allow replication by others?
Yes
If applicable, is the statistical analysis and its interpretation appropriate?
Yes
Are all the source data underlying the results available to ensure full reproducibility?
Yes
Are the conclusions drawn adequately supported by the results?
Yes
Competing Interests: No competing interests were disclosed.
Reviewer Expertise: Systematic reviews, overview methodology, physical activity in chronic disease
Alongside their report, reviewers assign a status to the article:
Invited Reviewers | ||
---|---|---|
1 | 2 | |
Version 2 (revision) 03 Apr 19 |
||
Version 1 09 Jan 19 |
read | read |
Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list:
Sign up for content alerts and receive a weekly or monthly email with all newly published articles
Already registered? Sign in
The email address should be the one you originally registered with F1000.
You registered with F1000 via Google, so we cannot reset your password.
To sign in, please click here.
If you still need help with your Google account password, please click here.
You registered with F1000 via Facebook, so we cannot reset your password.
To sign in, please click here.
If you still need help with your Facebook account password, please click here.
If your email address is registered with us, we will email you instructions to reset your password.
If you think you should have received this email but it has not arrived, please check your spam filters and/or contact for further assistance.
Comments on this article Comments (0)